Reversal of the Transcriptome by Prostaglandin E2 during Myofibroblast Dedifferentiation
Authors:
- 1 January 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 54 (1) , 114-127
Abstract
Myofibroblasts, the major effector cells in pathologic fibrosis, derive from the differentiation of fibroblasts driven by mediators such as transforming growth factor-β1 (TGF-β1) and biomechanical signals. Although the myofibroblast has traditionally been considered a terminally differentiated cell, the lipid mediator prostaglandin E2 (PGE2) has been shown to not only prevent but also reverse myofibroblast differentiation, as characterized by the ability of PGE2 to diminish expression of collagen I and α-smooth muscle actin in established myofibroblasts. Here, we use microarrays to examine the extent of transcriptomic changes that occur during TGF-β1–induced differentiation and PGE2-induced dedifferentiation of myofibroblasts. Normal primary human adult lung fibroblasts were cultured for 24 hours with or without TGF-β1 and treated for 48 hours with PGE2. Gene expression levels were assessed from total RNA on the Affymetrix U219 microarray. TGF-β1 up-regulated 588 genes and down-regulated 689 genes compared with control cells. PGE2 reversed the expression of 363 (62%) of the TGF-β1–up-regulated genes and 345 (50%) of the TGF-β1–down-regulated genes. Genes up-regulated by TGF-β1 and reversed by PGE2 were enriched in annotations for Cell Adhesion, Contractile Fiber, and Actin Binding, whereas genes down-regulated by TGF-β1 but subsequently reversed by PGE2 were enriched in annotations for Glycoprotein, Polysaccharide Binding, and Regulation of Cell Migration. Surprisingly, the genes whose expression was affected by PGE2 differed between TGF-β1–induced myofibroblasts and undifferentiated fibroblasts. These data demonstrate the capacity of PGE2 to effect marked global alterations in the transcriptomic program of differentiated myofibroblasts and emphasize the considerable plasticity of these cells.Keywords
This publication has 45 references indexed in Scilit:
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Inhibition of protein translation as a novel mechanism for prostaglandin E 2 regulation of cell functionsThe FASEB Journal, 2013
- Treatment of Idiopathic Pulmonary Fibrosis With AmbrisentanAnnals of Internal Medicine, 2013
- Matrix Stiffness–Induced Myofibroblast Differentiation Is Mediated by Intrinsic MechanotransductionAmerican Journal of Respiratory Cell and Molecular Biology, 2012
- The Role of Endothelin-1 in the Pathogenesis of Idiopathic Pulmonary FibrosisBioDrugs, 2010
- Gene expression profiling reveals novel TGFβ targets in adult lung fibroblastsRespiratory Research, 2004
- Prostaglandin E2 Inhibits Fibroblast to Myofibroblast Transition via E. Prostanoid Receptor 2 Signaling and Cyclic Adenosine Monophosphate ElevationAmerican Journal of Respiratory Cell and Molecular Biology, 2003
- Myofibroblasts and mechano-regulation of connective tissue remodellingNature Reviews Molecular Cell Biology, 2002
- Fibroblast growth factor reversal of the corneal myofibroblast phenotype.2001
- Transforming Growth Factor-β1 Promotes the Morphological and Functional Differentiation of the MyofibroblastExperimental Cell Research, 2000